Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

HMG-CoA reductase inhibitor adverse event reports that FDA received for the drugs of this class

Kind of class
Pharmacologic class (FDA Established Pharmacologic Class)
Drug pages
13

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

HMG-CoA reductase inhibitor is a pharmacologic class: an FDA Established Pharmacologic Class. The class has 13 drug pages on this site.

From January 2004 to June 2026, FDA received 204,462 adverse event reports that name a drug of the class. In these reports the drug is a suspect or interacting product. A report that names two drugs of the class counts one time for each.

FDA received 6,978 reports in the 12 months to June 2026 and 7,503 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 6,978 (0.5%) name a drug of the class. Reports from consumers or other non-health professionals were 35.7% of the reports that name a drug of the class and 45.8% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

Pharmacologic class

The Established Pharmacologic Class (EPC) of FDA is the class on the label of a drug. The site puts a drug in the class that its reports have most often.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs of the class

The rows are in order of name. A brand name and its generic name are separate rows, because reporters name them separately.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drug pages of the class HMG-CoA reductase inhibitor, in order of name
DrugName typeReportsReports, 12 months to June 2026
Atorvastatin calciumGeneric name20,120595
CrestorRosuvastatinBrand name44,259681
FluvastatinGeneric name1,42161
Fluvastatin sodiumGeneric name1,26624
LipitorAtorvastatin calciumBrand name55,172356
LivaloPitavastatin calciumBrand name1,79930
LovastatinGeneric name1,97230
PitavastatinGeneric name73183
Pravastatin sodiumGeneric name3,767156
RosuvastatinGeneric name20,1832,916
Rosuvastatin calciumGeneric name7,923906
SimvastatinGeneric name35,5011,032
ZocorSimvastatinBrand name10,348108

Reaction lookup

These are the reaction terms that the reports of the class record. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 3,335 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 203,938 of the 204,462 reports (99.7%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

The table shows the first 50 of 3,335 terms.

Reaction terms in the reports that name a HMG-CoA reductase inhibitor drug, most reports first
Reaction term (MedDRA) and plain meaningReportsShare of the 204,462 reports
Myalgiamuscle pain24,41411.9%
Type 2 diabetes mellitustype 2 diabetes12,5676.1%
Rhabdomyolysismuscle breakdown11,4155.6%
Fatiguetiredness10,5065.1%
Arthralgiajoint pain10,1725%
Pain in extremitypain in an arm or leg9,8454.8%
Painpain, site not specified9,7674.8%
Drug interactionan interaction between medicines9,4984.6%
Dyspnoeashortness of breath9,3484.6%
Muscle spasmsmuscle cramps9,2934.5%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)9,1514.5%
Drug ineffectivethe medicine did not work as expected8,9874.4%
Astheniaweakness or lack of energy8,6184.2%
Nauseafeeling sick8,3554.1%
Malaisegeneral feeling of being unwell8,1524%
Headachehead pain7,9743.9%
Muscular weaknessmuscle weakness7,5923.7%
Dizzinesslight-headedness or unsteadiness7,1813.5%
Diarrhoealoose or frequent stools6,5613.2%
Falla fall6,0683%
Vomitingbeing sick5,9632.9%
Blood creatine phosphokinase increased5,8002.8%
Off label useused for a purpose or in a way not on the label5,1612.5%
Myocardial infarctionheart attack5,1032.5%
Cough5,0892.5%
Blood cholesterol increasedraised cholesterol4,9572.4%
Insomniadifficulty sleeping4,9312.4%
Pruritusitching4,8092.4%
Gait disturbancedifficulty walking4,5132.2%
Pyrexiafever4,5052.2%
Chest pain4,4262.2%
Back pain4,3662.1%
Weight decreasedweight loss4,3572.1%
Abdominal pain upperupper stomach pain4,2932.1%
Abdominal painstomach or belly pain4,2862.1%
Hypertensionhigh blood pressure4,1562%
Constipation3,8351.9%
Rashskin rash3,7151.8%
Cerebrovascular accidentstroke3,6451.8%
Acute kidney injurysudden loss of kidney function3,6241.8%
Pneumonialung infection3,5501.7%
Blood pressure increaseda raised blood pressure reading3,2791.6%
Feeling abnormalfeeling odd or not right3,2681.6%
Asthma3,2451.6%
Deaththe patient died; cause not stated by this term3,1411.5%
Myopathy2,9221.4%
Diabetes mellitusdiabetes2,9061.4%
Depressionlow mood2,8721.4%
Hypotensionlow blood pressure2,8581.4%
Amnesiamemory loss2,8571.4%

Download all 3,335 terms of the class (CSV)

The counts add to more than 204,462 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Reports by month

Reports that name a HMG-CoA reductase inhibitor drug, by month, five years to June 2026
05001,00020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Outcomes, patients and reporters

Outcomes in the reports of the class HMG-CoA reductase inhibitor
OutcomeReportsShareShare as a bar
Death13,3596.5%
Life-threatening9,1534.5%
Hospitalization (initial or prolonged)50,23324.6%
Disability or Permanent Damage12,3106%
Congenital Anomaly/Birth Defect7590.4%
Other Serious (Important Medical Events)111,16354.4%
Not serious53,14426%

An outcome in a report is not proof that a drug was the cause. The reporter gives the outcome, and FDA does not verify it. A report can have more than one outcome. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Age of the patient in the reports of the class HMG-CoA reductase inhibitor
AgeReportsShareShare as a bar
Under 21170.1%
2 to 111210.1%
12 to 172350.1%
18 to 447,5903.7%
45 to 6454,86126.8%
65 to 7440,40919.8%
75 and over33,02816.2%
Age not given68,10133.3%
Type of reporter in the reports of the class HMG-CoA reductase inhibitor
ReporterReportsShareShare as a bar
Physician48,01923.5%
Pharmacist11,6145.7%
Other health professional41,13420.1%
Lawyer11,5895.7%
Consumer or non-health professional72,92735.7%
Not given19,1799.4%

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Reported Reactions. HMG-CoA reductase inhibitor: adverse event reports that FDA received. https://reportedreactions.com/class/hmg-coa-reductase-inhibitor/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The class of a drug is the Established Pharmacologic Class that openFDA attaches to its reports most often. When the reports have none, it is the class in the NDC Directory. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Which drugs are in the HMG-CoA reductase inhibitor class on this site?

Atorvastatin calcium, Crestor, Fluvastatin, Fluvastatin sodium, Lipitor, Livalo and 7 more, in order of name. The class of a drug comes from the pharmacologic class (EPC) on its FDA label.

Can the table of drugs rank the drugs?

No. FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Drugs also differ in the conditions that they treat and in their time on the market.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.